Hester Biosciences Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the company reported net sales/income from operations of INR 285.23 million compared to INR 241.77 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 81.53 million compared to INR 62.66 million a year ago. Net profit from ordinary activities after tax was INR 58.01 million or INR 6.82 per basic and diluted share before and after extraordinary items not annualized compared to INR 47.58 million or INR 5.59 per basic and diluted share before and after extraordinary items not annualized a year ago. The company has invested INR 61.9 million as a capex. For the nine months, the company reported net sales/income from operations of INR 882.85 million compared to INR 727.11 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 254.25 million compared to INR 192.60 million a year ago. Net profit from ordinary activities after tax was INR 177.68 million or INR 20.89 per basic and diluted share before and after extraordinary items not annualized compared to INR 137.18 million or INR 16.13 per basic and diluted share before and after extraordinary items not annualized a year ago. The total investment in capex stands at INR 112.7 million.